Abstract: A composition of psilocin that is stable including at least one agent or chemical modification that provides enhanced stability. A method making stable psilocin, by providing a formulation of psilocin including at least one agent or chemical modification that provides enhanced stability. A method of treatment of a disease or condition, by administering a composition of psilocin that is stable to an individual and treating the disease or condition.

Abstract: The present invention discloses a method to recover and restore dendritic and synaptic neuron connections that have been degraded or destroyed by neurodegenerative diseases. In the present invention tryptamines are used to induce neuro plasticity and restore both dendritic density and synaptic connections of neurons in the brain. In the preferred embodiment LSD given in micro doses can induce dendritic and synaptic genesis in neuronal networks and improve the quality of life of people with neurodegenerative diseases such as Alzheimer's, Huntington's, Multiple Sclerosis, Parkinson's and Frontotemporal dementia.

Abstract: A transmucosal psychoactive alkaloid composition including a psychoactive alkaloid extract or synthetic psychoactive alkaloid. The alkaloids in the extract are predominantly dephosphorylated rather than phosphorylated. The transmucosal psychoactive alkaloid composition also includes a mucoadhesive polymer, a carrier, and optional further excipients. The non-ingestive composition may be taken orally through the mucosa. A process for obtaining an oral transmucosal psychoactive alkaloid composition includes dephosphorylating the alkaloid during extraction, purifying the extracted alkaloid and standardizing to a specific concentration by adding measured quantities of excipients.

Abstract: Described herein are combined fungal compositions for treating, prophylaxis of, or ameliorating symptoms of one or more adverse reactions triggered by an infectious disease or condition that causes an inflammatory response. In one aspect the composition comprises an aqueous or solid fraction of Trametes versicolor and Fomitopsis officinalis mycelium, fermented substrates thereof, or combinations thereof.

Abstract: Disclosed are novel C4-carboxylic acid-substituted tryptamine derivative compounds and pharmaceutical and recreational drug formulations containing the same. The pharmaceutical formulations may be used to treat brain neurological disorders.

Abstract: Disclosed are an Inonotus Obliquus dextran, a preparation method and application thereof, and relates to the field of medicines. The dextran has a structural formula as follows: By optimizing the extraction and isolation process, the present disclosure obtains an Inonotus Obliquus dextran, which is structurally determined to be a new polysaccharide. The Inonotus Obliquus dextran prepared by the present disclosure is combined with gemcitabine hydrochloride to inhibit tumor cells with anti-tumor activity against pancreatic cancer, in addition to reduce the dosage of chemotherapeutic drugs as well as the adverse effects of chemotherapeutic drugs.

Abstract: Described herein are mushroom compositions and methods for treating, prophylaxis of, or ameliorating symptoms of one or more adverse reactions triggered by an infectious disease or condition that increases an anti-inflammatory response in a subject with such compositions. In one aspect the composition comprises an aqueous or solid fraction of a mycelium, a fermented substrate thereof, or a combination thereof optionally combined with one or more buffering agents, ethanol, and water.

Abstract: A composition for modulating intestinal permeability and/or treating and/or preventing leaky gut related diseases including a Chinese herbal compound material or a Chinese herbal compound extract is provided. The Chinese herbal compound material includes Ganoderma, red jujube, longan and lotus seed. Moreover, the Chinese herbal compound extract includes a Ganoderma extract, a red jujube extract, a longan extract and a lotus seed extract.

Abstract: Described herein are neurotrophic and nootropic compositions and methods for treating subjects with such compositions. In one aspect the composition comprises one or more tryptamines or in pure form or extracts from psilocybin containing mushrooms, or combinations thereof optionally combined with one or more phenethylamines or amphetamines in pure form or extracts from a plant or mushroom, or combinations thereof, optionally one or more erinacines or hericenones in pure form, extracts from Hericium mushroom species (e.g., H. erinaceus, H. coralloides, H. ramosum) or combinations thereof, optionally one or more cannabinoids in pure form or extracts from Cannabis sativa, Cannabis sativa, Cannabis indica, or Cannabis ruderalis, optionally, one or more adversive compounds, and optionally one or more pharmaceutically acceptable excipients.

Abstract: The present disclosure relates to the synergistic combination of a sulforaphane precursor, an enzyme capable of converting the sulforaphane precursor to sulforaphane, a cofactor of the enzyme, and a glucan. The present disclosure also relates to the synergistic combination of sulforaphane or a derivative thereof and a glucan. The present disclosure also relates to the synergistic combination of a broccoli extract or powder and a glucan. The glucan may be a ?-glucan. The glucan may be provided in a mushroom extract or powder selected from one or more of a maitake, a shiitake, or a reishi mushroom. Compositions and methods relating to these combinations are described.

Abstract: Described herein are neurotrophic and nootropic compositions and methods for treating subjects with such compositions. In one aspect the composition comprises one or more tryptamines or in pure form or extracts from psilocybin containing mushrooms, or combinations thereof optionally combined with one or more phenethylamines or amphetamines in pure form or extracts from a plant or mushroom, or combinations thereof, optionally one or more erinacines or hericenones in pure form, extracts from Hericium mushroom species (e.g., H. erinaceus, H. coralloides, H. ramosum) or combinations thereof, optionally one or more cannabinoids in pure form or extracts from Cannabis sativa, Cannabis sativa, Cannabis indica, or Cannabis ruderalis, optionally, one or more adversive compounds, and optionally one or more pharmaceutically acceptable excipients.

Abstract: A traditional Chinese medicine composition, made from cassia twig, poria, Cortex moutan, Radix paeoniae alba, peach kernel in equal proportions. The traditional Chinese medicine composition comprises paeoniflorin, amygdalin, benzoylpaeoniflorin, cinnamic acid, paeonol, and cinnamaldehyde. The composition has the advantages of high production efficiency, high content of effective ingredients, high transfer rate of poria acid, reduced hygroscopicity, and improved dissolution of index ingredients.

Abstract: The invention provides methods and systems for detecting a biomarker in a synovial fluid wherein the system also includes a control to ensure that the test sample is indeed synovial fluid. The biomarkers and the control for synovial fluid can be identified using proteomic methods, including but not limited to antibody based methods, such as an enzyme-linked immunosorbant assay (ELISA), a radioimmunoassay (RIA), or a lateral flow immunoassay.

Abstract: The present disclosure is directed to a composition for managing exaggerated sebum production in oily-prone skin, the composition containing: (1) a mixture of at least: (a) from about 0.02 to about 1% by weight of an ingredient capable of activating cannabinoid type-2 receptors (“CB2”); (b) from about 0.1 to about 3% by weight of a blend of Tetraselmis chuii and Fucus spiralis algae extracts; (c) from about 0.1 to about 4% by weight of an extract of Centella asiatica; and (d) from about 0.01 to about 0.05% by weight of an extract of Tulsi, wherein all weights are based on total weight of the composition; (2) optionally, an emulsifier; and (3) a dermatologically acceptable carrier, wherein the composition has a pH ranging from about 4.5 to about 5.5.

Abstract: This disclosure pertains to new compositions and methods comprising a first serotonergic drug and a second serotonergic drug. In one embodiment, the compositions disclosed herein are used for a method of regulating a neurotransmitter receptor, e.g., a serotonin receptor. In one embodiment, the compositions disclosed herein comprise purified compounds, e.g., a purified psilocybin derivative, a purified cannabinoid, a purified terpene, a purified tryptamine, purified LSD, and/or purified MDMA.

Abstract: Method for making a Cannabinoid molecule bath bomb by first etching the surface of at least one of ?9 Tetrahydrocannabinol molecule and Cannabidiol molecule. The etched Cannabinoid molecule is then combined with Sodium Bicarbonate, Citric acid, Magnesium Chloride, and a viscous binder. Once the ingredients have been combined the resulting mixture is dried to form a Cannabinoid molecule bath bomb.

Abstract: The present disclosure relates to a composition for preventing or treating metabolic diseases, the composition containing Artemisiae capillaris Herba and Citrus unshiu Peel complex extracts as active ingredients. Specifically, in the Artemisiae capillaris Herba and Citrus unshiu Peel complex extracts according to the present disclosure, the content of ingredients useful for prevention of metabolic diseases including obesity is much higher than in extracts obtained only from Artemisiae capillaris Herba. In addition, when a high-fat diet mouse model is administered the complex extracts, the levels of total cholesterol, LDL, and triglycerides in the blood are reduced. Accordingly, the complex extracts of the present disclosure may be used as a composition or functional material for preventing or treating metabolic diseases including obesity, hyperlipidemia, and hypercholesterolemia.

Abstract: A method for processing traditional Chinese medicine using a calcium-based ion solution and an application thereof. A solution formed by a calcium-based ion solution and Chinese spirits is used to soak a traditional Chinese medicine prescription; the calcium-based ion solution refers to a solution containing calcium ions with a mass percentage of 0.3-10%; and the Chinese spirits is a spirit containing more than 35% alcohol by volume. Also provided is an application of a soaking liquid for processing traditional Chinese medicine in preparing, from a traditional Chinese medicine prescription, a meridians and collaterals administration agent applied on skin, a preparation extracted from traditional Chinese medicine soaked using a soaking solution formed by “a calcium-based ion solution and a spirit” has a better effect of guiding skin penetration.

Abstract: A Ganoderma lucidum polysaccharides composite composition comprising, based on a total composition: 1 to 5 wt. % ?-glucan extract, 1 to 5 wt. % Ganoderma lucidum mycelium extract, 1 to 5 wt. % Trametes versicolor mycelium extract, 1 to 5 wt. % Tremella fuciformis Berk extract, 1 to 5 wt. % Auricularia auricula-judae extract, 1 to 5 wt. % Hericium erinaceus extract, 1 to 3 wt. % Ganoderma lucidum fruiting body extract, and water.

Abstract: A method of preparing a high yield of mushroom ?-glucan is provided. The method includes: providing a liquid culture to culture the mushroom mycelium by fermentation, to increase the yields of the mushroom mycelium and polysaccharide, wherein the liquid culture comprises at least two ingredients selected from the groups consisting of glucose, trehalose, a dietary fiber and mannose or derivatives thereof; and rupturing the mushroom mycelium with a continuous multiple-ultrasonic equipment; and removing insoluble matters from the liquid culture. A method of preparing highly pure mushroom ?-glucan powder and solution and the products thereof are also provided. By the method of the present disclosure, the yield of mushroom ?-glucan is effectively increased, its activity loss is reduced, and the stability of product thereof is improved.

Abstract: A biocomposite powder comprising 20-95% (w/w) chitin-glucan complex (CGC), and up to 50% (w/w) mannose-containing polysaccharides, wherein the biocomposite powder has a bulk density of 0.5 to 1.0 g/cm3, and wherein greater than 60% (w/w) of the particles of the biocomposite powder have a size below 212 ?m.

Abstract: Entomopathogenic fungal strains, compositions, and methods of using the strains for reducing overall insect damage.

Abstract: The present invention relates to animals and more specifically to insects. In more details the invention relates to an edible composition or insect artificial diet comprising bacteria, fungi or any fragment or spore thereof for use as a vaccine in preventing a microbial disease or infection in an insect. Still, the present invention relates to preventive methods and different uses relating to said compositions or bacteria, fungi or fragments or spores thereof.

Abstract: The present invention provides a composition and food for improving skin condition containing exopolysaccharides produced by Ceriporia lacerata, a mycelial culture fluid of Ceriporia lacerata comprising the exopolysaccharides, a dry powder of the mycelial culture fluid or an extract of the mycelial culture fluid as an active ingredient. The composition and the food for improving skin condition have a superior skin whitening effect, wrinkle improving effect, skin moisturizing effect or skin anti-aging effect.

Abstract: The present invention relates to a composition for the synthesis of ATP as an energy supplementation. The composition comprises a plant extract or a plant fraction suitable to produce ATP upon exposure to light. The present invention also relates to the isolation of such plant extract and to its use in energy drinks.

Abstract: Described herein is a method for blastospore-based insect control products of entomopathogenic fungi including either B. bassiana or I. fumosorosea that produces high concentrations of stable, effective spores by identifying nutritional and environmental conditions required for the rapid production of high concentrations of a stable and infective yeast-like blastospore composition.

Abstract: The invention provides a synthetic combination of a crop and at least one fungal endophyte, wherein the crop is a host plant of the endophyte. Provided are also methods and compositions for producing such synthetic combinations. The endophyte reproduces and enhances the agronomic characteristics of the crop. Methods for inoculating the host plant with the endophyte, for propagating the host-endophyte combination, and for detecting the presence of the endophyte and of its metabolites within a host plant are also described.

Abstract: Disclosures of the present invention describe a method of treatment of cancer cells by using pharmaceutical composition. In the present invention, it particularly adopts an ethanol extract of Taiwanofungus camphorata (TCEE), an ethanol extract of Ganoderma lucidum (GLEE) or a combination of the TCEE and the GLEE as the a pharmaceutical composition for use in causing the apoptosis of lung cancer cells A594, hepatoma cells Huh 7, breast cancer cells MDA-MB 231, and colorectal cancer cells HT 29. Moreover, related experimental data have proved that, the pharmaceutical composition can not only be used for adjunctively treating cancer, but also possesses many healthy effects, including: detoxification, enhancing immunity, and increasing appetite.

Abstract: The present invention relates to an extracellular polysaccharide produced by Ceriporia lacerata, a culture medium of Ceriporia lacerata hyphae including the extracellular polysaccharide, a composition for immunoregulation containing, as an active ingredient, dried powder of the hyphae culture medium or an extract of the hyphae culture medium, a pharmaceutical composition for preventing or treating an immune disease, and a health food for immunoregulation. The composition of the present invention has an excellent effect on immune enhancement and overactive immune response inhibition.

Abstract: A method is presented for treating herpes simplex virus (HSV) infection comprising: (a) locally administering a substance that induces a delayed type hypersensitivity (DTH) response to a patient at a site of an HSV lesion to induce a DTH response at the site of the lesion during one or more outbreaks of the HSV infection.

Abstract: The present invention relates to a blood pressure lowering composition which contains as an active ingredient exopolysaccharide produced by means of Ceriporia lacerata, a Ceriporia lacerata mycelium culture medium comprising same, or dry powder or an extract of same. The composition can be used as an antihypertensive for preventing or treating hypertension or cerebral apoplexy or as a functional health food having antihypertensive effect.

Abstract: The present invention relates to a pharmaceutical composition for treating and preventing degenerative neurological disorders, containing, as an active ingredient, a mixture extract of two or more types selected from the group consisting of Moutan Root Bark, Angelica Dahurica Root, and Bupleurum Root, or a fraction thereof.

Abstract: Provided is a kampo medicine for treating multimorbidity of Alzheimer-type dementia or mild cognitive impairment and at least one disease from the group consisting of overactive bladder, constipation, and chronic kidney disease with one drug. A kampo medicine for treating multimorbidity with one drug, comprising a drug combination of orengedokuto and ryokeijutsukanto as an active ingredient, wherein the kampo medicine improves a cognitive function in Alzheimer-type dementia or mild cognitive impairment and relieves and treats at least one disease from overactive bladder, constipation, and chronic kidney disease complicated by Alzheimer-type dementia or mild cognitive impairment at a high rate with one drug.

Abstract: Provided are certain methods useful in the treatment of cancer comprising administering a compound of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the cannabinoid CB2 receptor;

Abstract: The present invention relates to a pharmaceutical composition comprising non-decarboxylated ?9 Tetrahydrocannabinol (THC), Cannabidiol (CBD), and at least one small molecule selected from Citric Acid, Ascorbic Acid, Citrus Essential Oil(s), Lecithin, one or more sugar(s), Resveratrol, and combinations thereof, wherein the composition exhibits enhanced therapeutic potency of THC and/or CBD. The present invention is further directed to methods of treating one or more disease(s) or disorder(s) modulated by the activation of the Cannabinoid CB1 and/or CB2 receptors, by administering a therapeutically effective amount of the composition of the present invention to a subject in need thereof.

Abstract: The invention generally relates to an immunomodulatory protein and a chemotherapeutic agent for simultaneous, contemporaneous or sequential use in the treatment of diseases, more particularly of proliferative diseases, still more particularly of cancer(s), to a combination of an FIP and a chemotherapeutic agent, as well as to the medical and biotechnological applications thereof, more particularly in the field of the treatment of diseases, more particularly of proliferative diseases, still more particularly of cancer(s).

Abstract: Disclosed are methods for treating, preventing and alleviating obesity, fatty liver syndrome, diabetes, one or more metabolic syndrome conditions or complications and/or cancer comprising administering an effective amount of ostreolysin, its functionally related variant, or an extract or mushroom extract comprising the same to subjects in need thereof.

Abstract: A system and method may allow a person to rotate a skin care product based on the current climate to help skin transition to and react to changes in temperature and humidity the air. For example, each moisturizer may be formulated to support skin needs for a specific climate, such as tropical climate (i.e., humid and hot air), a desert climate (i.e., dry and hot air), a temperate climate (i.e., normal and mild air), and/or a polar climate (i.e., cold and dry air).

Abstract: A pentosidine production inhibitor including a lactic acid bacterium fermentation product as an active ingredient, which has a stronger action and a high safety as a component having an action of inhibiting production of pentosidine.

Abstract: A method of inducing the production of insulin in the body by an individual smelling a composition of a solution including testosterone, and inducing the production of insulin in the body of the individual. A method of treating diabetes type 2 by an individual having diabetes type 2 smelling a composition of a solution including testosterone, inducing the production of insulin in the body of the individual, and treating diabetes type 2 in the individual.

Abstract: Disclosed herein is a novel use of a polysaccharide mixture for the treatment of hyperglycemia and/or disorders related thereto (e.g., diabetes mellitus). The polysaccharide mixture comprises about 30-50% (wt %) of ?(1?3) glucan and ?(1?6) glucan, and has a molecular weight of at least 500,000. The polysaccharide mixture may be administered to a subject suffering from hyperglycemia in a dose of about 1 to 1,000 mg/Kg to ameliorate or alleviate symptoms associated with hyperglycemia.

Abstract: Therapeutic compositions for addressing physiological stresses and aging include an immune modulator and one or more adaptogenic nutrients. Some non-limiting examples of immune modulators include as transfer factor, low molecular weight fraction immune modulators and/or other low molecular weight fractions of colostrum, egg or any other source of transfer factor or low molecular weight fraction immune modulators. Methods for administering immune modulators and adaptogenic nutrients to a subject to address the effects of physiological stresses and aging in the body of the subject, such as inflammatory responses, are also disclosed.

Abstract: The present invention is directed to a therapeutic method of treatment of diabetes mellitus, particularly diabetes which acquires multiple drug resistance, comprising administering a therapeutically effective amount of Chinese herbal medicine to a subject in need. The Chinese herbal medicine is the decocting extract including the mixture of raw oyster shell powder, raw Os Draconis, Haematitum, Magnetitum, radix Achyranthis Bidentatae, rhizoma Dioscoreae, radix Paeoniae Rubra, radix Rehmanniae, and semen Platycladi.

Abstract: A therapeutic method of treatment of diabetes mellitus, particularly diabetes which acquires insulin resistance, including administering a therapeutically effective amount of Chinese herbal medicine to a subject in need. The Chinese herbal medicine is the decocting extract including the mixture of raw oyster shell powder, raw Os Draconis, Haematitum (Hematite), Magnetitum (Magnetite), radix Achyranthis Bidentatae (Achyranthes bidentata), rhizoma Dioscoreae (Dioscoreae Rhizoma), radix Paeoniae Rubra (Paeoniae Radix Rubra), radix Rehmanniae (Rehmannia), and semen Platycladi (Platycladi Semen).

Abstract: Immunogenic compositions, cancer vaccines and methods for treating cancer comprising FMS, the fucose-enriched polysaccharide fraction from Reishi F3, are provided. Compositions comprise fucose-enriched Reishi polysaccharide fraction (FMS) MW=˜35 kDa, wherein the FMS is isolated by size-exclusion chromatography from Reishi F3, and the FMS comprises polysaccharides having primarily a backbone selected from 1,4-mannan and 1,6-?-galactan, wherein the backbone is linked to a terminal fucose-containing side-chain Immunogenic compositions comprising glycolipid adjuvants are provided. Antibodies generated by immunogenic compositions disclosed herein bind cancer cells comprising antigens Globo H, Globo H, Gb3, Gb4, Gb5 (SSEA-3) and SSEA-4 on the cell surface.

Abstract: The present invention relates to a proteolytic extract obtained from bromelain for the treatment of connective tissue diseases. In particular, the present invention relates to a pharmaceutical composition comprising a proteolytic extract obtained from bromelain for the treatment of diseases such as Dupuytren's disease and Peyronie's disease.

Abstract: The pharmaceutical composition is a formulation prepared by the raw materials in parts by weight: 1-300 parts of chlorogenic acid and 1-50 parts of Ganoderma lucidum spore oil, and the preparative process for said pharmaceutical composition was provided. Chlorogenic acid can be used compatibly with Ganoderma lucidum spore oil, with a synergistic effect. Inclusion technique is applied in product development to improve stability of oily liquid material Ganoderma lucidum spore oil and solid material chlorogenic acid obtained from the extract of Eucommia leaves. After inclusion by the inclusion technology, the liquid drugs become powder, and thus easily oxidized natural products could be protected. Moreover, the damage for active ingredients caused by air can be prevented, and the stability and the taste may get improved.

Abstract: The subject invention provides Coriolus versicolor extracts, pharmaceutical compositions comprising the Coriolus versicolor extracts, methods of preparation, and therapeutic uses thereof. Advantageously, the subject Coriolus versicolor extract has immunomodulatory, anti-tumor, anti-microbial, and antiviral effects. In a preferred embodiment, the subject invention can be used to inhibit the metastatic spread of cancer cells. In certain preferred embodiments, the subject invention can be used to treat glioblastoma multiforme, nasopharyngeal carcinoma, breast carcinoma, lung carcinoma, prostate cancer, and colon carcinoma, as well as bacterial, viral, fungal, protozoan, and/or other microbial infection.

Abstract: The present invention provides a method for manufacturing fungal pharmaceutical composition, used for extracting a glycosaminoglycan fiber from a fungal cell wall. Differing from the glycosaminoglycan fiber produced by using a fabrication method proposed by Taiwan patent No. 442496 showing many drawbacks including low extraction percentage, coarse fiber, and having light-yellow color, the glycosaminoglycan fiber manufactured by using this novel method reveals the advantages of high extraction percentage, fine fibers, and showing white color. So that, the novel glycosaminoglycan fiber produced by using the present invention's method is suitable for being processed to an excipient.

Abstract: Described herein is an aerosol hairspray product including a container including a container wall which encloses a reservoir. The reservoir includes from about 40% to about 70% of a hairstyling formulation and from about 30% to about 60% of a dimethyl ether propellant. The hairstyling formulation includes water, one or more hairstyling polymers, and from about 0.05% to about 2% alcohol. A spraying device is attached to the container. The spraying devices includes a valve including a valve housing including a vapor tap including a vapor tap area. A dip tube is connected to the valve. The dip tube includes a dip tube orifice including a dip tube orifice area. The ratio of the vapor tap area to the dip tube orifice area is from about 0.005 to about 0.15.